Avalyn Pharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Novo Holdings A/S, was filed 05 May 2026.
Avalyn Pharma Inc.: what insiders have been doing
Every trade that managers of Avalyn Pharma Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. From 14 November 2025 to 14 November 2026, the disclosure feed for Avalyn Pharma Inc. logged 20 filings by 5 insiders.
Purchases and sales both appear in the filings: 3 purchases (2 insiders, €17.1M) and 4 sales (1 insider, €6.0M). Netting one side against the other leaves €11.1M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 2 major shareholders. At €8.5M, the purchase published on 5 May 2026 by Novo Holdings A/S is the largest of the period.
In the case of 3 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 5 May 2026, 196 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 20 filings in twelve months, the company is quieter than the median of 24 filings across the 3,183 companies we follow on the same exchange. Since 2026, the database holds 3 purchases and 4 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Drägerwerk AG & Co. KGaA. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +9.3%Entry US$27.71 · Close 13 Nov 2026 US$30.28
- +4.2%Entry US$29.07 · Close 13 Nov 2026 US$30.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 173,661 shares@ US$29.060.49% mcap75.4% of flowCommon StockSEC:0001193125-26-457571:0
- 1,339 shares@ US$29.750.0038% mcap0.6% of flowCommon StockSEC:0001193125-26-457571:1
- 5,565 shares@ US$29.560.016% mcap2.4% of flowCommon StockSEC:0001193125-26-457571:2
- 47,889 shares@ US$30.280.14% mcap21.5% of flowCommon StockSEC:0001193125-26-457571:3
- 555,555 shares@ US$18.00100.0% of flowVoting Common StockSEC:0001388325-26-000021:1Canonical exit: 30 Jul 2026 (T+90)
- 727,585 sharesCommon StockSEC:0001193125-26-205201:0
- 80,291 sharesCommon StockSEC:0001193125-26-205201:1
- 872,868 sharesCommon StockSEC:0001193125-26-205201:2
- 225,843 sharesCommon StockSEC:0001193125-26-205201:3
- 377,948 sharesCommon StockSEC:0001193125-26-205201:4
- 3,327,734 sharesVoting Common StockSEC:0001388325-26-000021:0
- 277,778 shares@ US$18.000.29% mcap100.0% of flowCommon StockSEC:0001193125-26-201894:2Canonical exit: 30 Jul 2026 (T+90)
- 277,777 shares@ US$18.000.29% mcap50.0% of flowCommon StockSEC:0001193125-26-201887:5Canonical exit: 30 Jul 2026 (T+90)
- 277,778 shares@ US$18.000.29% mcap50.0% of flowCommon StockSEC:0001193125-26-201887:2Canonical exit: 30 Jul 2026 (T+90)
- 1,419,298 sharesCommon StockSEC:0001193125-26-201887:0
- 489,486 sharesCommon StockSEC:0001193125-26-201887:1
- 1,275,486 sharesCommon StockSEC:0001193125-26-201863:0
- 354,824 sharesCommon StockSEC:0001193125-26-201887:3
- 489,486 sharesCommon StockSEC:0001193125-26-201887:4
- 1,419,298 sharesCommon StockSEC:0001193125-26-201894:0
- 489,486 sharesCommon StockSEC:0001193125-26-201894:1
21 of 21 declarations
About Avalyn Pharma Inc.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendationsThe weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.
